Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers.

Next Previous
Search
Trial Profile

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders
  • Focus Adverse reactions; Registrational
  • Sponsors POZEN

    • Most Recent Events

    • 09 Jan 2017 According to an Aralez Pharmaceuticals Inc. media release, the company has submitted a Marketing Authorization Application (MAA) to the EMA for PA10040 (YOSPRALA) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers based on results from three trials (CTPs 700036117, 700048158 and 700225598)
    • 14 Nov 2016 According to an Aralez Pharmaceuticals media release, results of pooled post hoc analysis from this and other phase III study (Profile 36117) were presented at the annual American Heart Association Scientific Sessions.
    • 14 Nov 2016 Results of pooled post hoc analysis from this and other phase III study (Profile 36117), published in an Aralez Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top